vs

Side-by-side financial comparison of Baird Medical Investment Holdings Ltd (BDMD) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.

TRANSACT TECHNOLOGIES INC is the larger business by last-quarter revenue ($11.5M vs $8.0M, roughly 1.4× Baird Medical Investment Holdings Ltd). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-3.2M).

Baird Medical Investment Holdings Ltd is a healthcare-focused investment holding company mainly operating in the Chinese market. It invests in and manages businesses covering in vitro diagnostic devices, medical consumables, and community healthcare services, serving clinical institutions and individual consumers.

Roper Technologies, Inc. is a holding company that owns companies in the technology sector.

BDMD vs TACT — Head-to-Head

Bigger by revenue
TACT
TACT
1.4× larger
TACT
$11.5M
$8.0M
BDMD
More free cash flow
TACT
TACT
$3.8M more FCF
TACT
$589.0K
$-3.2M
BDMD

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
BDMD
BDMD
TACT
TACT
Revenue
$8.0M
$11.5M
Net Profit
$-11.4M
Gross Margin
82.1%
47.6%
Operating Margin
-131.3%
-10.1%
Net Margin
-142.7%
Revenue YoY
11.9%
Net Profit YoY
EPS (diluted)
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BDMD
BDMD
TACT
TACT
Q4 25
$11.5M
Q3 25
$13.2M
Q2 25
$8.0M
$13.8M
Q1 25
$13.1M
Q4 24
$10.2M
Q3 24
$10.9M
Q2 24
$11.6M
Q1 24
$10.7M
Net Profit
BDMD
BDMD
TACT
TACT
Q4 25
Q3 25
$15.0K
Q2 25
$-11.4M
$-143.0K
Q1 25
$19.0K
Q4 24
Q3 24
$-551.0K
Q2 24
$-319.0K
Q1 24
$-1.0M
Gross Margin
BDMD
BDMD
TACT
TACT
Q4 25
47.6%
Q3 25
49.8%
Q2 25
82.1%
48.2%
Q1 25
48.7%
Q4 24
44.2%
Q3 24
48.1%
Q2 24
52.7%
Q1 24
52.6%
Operating Margin
BDMD
BDMD
TACT
TACT
Q4 25
-10.1%
Q3 25
0.1%
Q2 25
-131.3%
-1.9%
Q1 25
-0.1%
Q4 24
-10.3%
Q3 24
-7.7%
Q2 24
-3.8%
Q1 24
-12.2%
Net Margin
BDMD
BDMD
TACT
TACT
Q4 25
Q3 25
0.1%
Q2 25
-142.7%
-1.0%
Q1 25
0.1%
Q4 24
Q3 24
-5.1%
Q2 24
-2.8%
Q1 24
-9.7%
EPS (diluted)
BDMD
BDMD
TACT
TACT
Q4 25
$-0.11
Q3 25
$0.00
Q2 25
$-0.01
Q1 25
$0.00
Q4 24
$-0.80
Q3 24
$-0.06
Q2 24
$-0.03
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BDMD
BDMD
TACT
TACT
Cash + ST InvestmentsLiquidity on hand
$20.4M
Total DebtLower is stronger
$8.4M
Stockholders' EquityBook value
$35.6M
$31.1M
Total Assets
$77.0M
$44.8M
Debt / EquityLower = less leverage
0.24×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BDMD
BDMD
TACT
TACT
Q4 25
$20.4M
Q3 25
$20.0M
Q2 25
$17.7M
Q1 25
$14.2M
Q4 24
$14.4M
Q3 24
$11.3M
Q2 24
$11.1M
Q1 24
$10.6M
Total Debt
BDMD
BDMD
TACT
TACT
Q4 25
Q3 25
Q2 25
$8.4M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BDMD
BDMD
TACT
TACT
Q4 25
$31.1M
Q3 25
$31.8M
Q2 25
$35.6M
$31.3M
Q1 25
$30.9M
Q4 24
$30.6M
Q3 24
$38.4M
Q2 24
$38.5M
Q1 24
$38.6M
Total Assets
BDMD
BDMD
TACT
TACT
Q4 25
$44.8M
Q3 25
$45.0M
Q2 25
$77.0M
$44.5M
Q1 25
$44.2M
Q4 24
$44.0M
Q3 24
$50.5M
Q2 24
$50.4M
Q1 24
$51.9M
Debt / Equity
BDMD
BDMD
TACT
TACT
Q4 25
Q3 25
Q2 25
0.24×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BDMD
BDMD
TACT
TACT
Operating Cash FlowLast quarter
$-3.2M
$609.0K
Free Cash FlowOCF − Capex
$-3.2M
$589.0K
FCF MarginFCF / Revenue
-40.7%
5.1%
Capex IntensityCapex / Revenue
0.6%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$7.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BDMD
BDMD
TACT
TACT
Q4 25
$609.0K
Q3 25
$3.6M
Q2 25
$-3.2M
$3.6M
Q1 25
$-161.0K
Q4 24
$2.4M
Q3 24
$327.0K
Q2 24
$636.0K
Q1 24
$-1.5M
Free Cash Flow
BDMD
BDMD
TACT
TACT
Q4 25
$589.0K
Q3 25
$3.6M
Q2 25
$-3.2M
$3.6M
Q1 25
$-171.0K
Q4 24
$2.4M
Q3 24
$259.0K
Q2 24
$499.0K
Q1 24
$-1.6M
FCF Margin
BDMD
BDMD
TACT
TACT
Q4 25
5.1%
Q3 25
27.1%
Q2 25
-40.7%
25.9%
Q1 25
-1.3%
Q4 24
23.2%
Q3 24
2.4%
Q2 24
4.3%
Q1 24
-14.9%
Capex Intensity
BDMD
BDMD
TACT
TACT
Q4 25
0.2%
Q3 25
0.5%
Q2 25
0.6%
0.1%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.6%
Q2 24
1.2%
Q1 24
1.0%
Cash Conversion
BDMD
BDMD
TACT
TACT
Q4 25
Q3 25
242.00×
Q2 25
Q1 25
-8.47×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons